Journal
AMERICAN JOURNAL OF GASTROENTEROLOGY
Volume 105, Issue 5, Pages 1140-1141Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/ajg.2010.15
Keywords
-
Categories
Ask authors/readers for more resources
Infliximab is a potent therapy for induction and maintenance of remission in Crohn's disease. Unfortunately, many patients lose response and/or develop allergic reactions caused by the chimeric antibody. By means of measuring the presence of antibodies against infliximab and the trough levels of the drug, it seems easier to predict whether patients will respond to intensified dose regimens or will rather benefit from a switch to alternative agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available